Matches in SemOpenAlex for { <https://semopenalex.org/work/W2986009663> ?p ?o ?g. }
- W2986009663 endingPage "23.e7" @default.
- W2986009663 startingPage "12" @default.
- W2986009663 abstract "The established method of the assessment of the risk for development of preeclampsia is to identify risk factors from maternal demographic characteristics and medical history; in the presence of such factors, the patient is classified as high risk and in their absence as low risk. Although this approach is simple to perform, it has poor performance of the prediction of preeclampsia and does not provide patient-specific risks. This review describes a new approach that allows the estimation of patient-specific risks of delivery with preeclampsia before any specified gestational age by maternal demographic characteristics and medical history with biomarkers obtained either individually or in combination at any stage in pregnancy. In the competing risks approach, every woman has a personalized distribution of gestational age at delivery with preeclampsia; whether she experiences preeclampsia or not before a specified gestational age depends on competition between delivery before or after the development of preeclampsia. The personalized distribution comes from the application of Bayes theorem to combine a previous distribution, which is determined from maternal factors, with likelihoods from biomarkers. As new data become available, what were posterior probabilities take the role as the previous probability, and data collected at different stages are combined by repeating the application of Bayes theorem to form a new posterior at each stage, which allows for dynamic prediction of preeclampsia. The competing risk model can be used for precision medicine and risk stratification at different stages of pregnancy. In the first trimester, the model has been applied to identify a high-risk group that would benefit from preventative therapeutic interventions. In the second trimester, the model has been used to stratify the population into high-, intermediate-, and low-risk groups in need of different intensities of subsequent monitoring, thereby minimizing unexpected adverse perinatal events. The competing risks model can also be used in surveillance of women presenting to specialist clinics with signs or symptoms of hypertensive disorders; combination of maternal factors and biomarkers provide patient-specific risks for preeclampsia that lead to personalized stratification of the intensity of monitoring, with risks updated on each visit on the basis of biomarker measurements. The established method of the assessment of the risk for development of preeclampsia is to identify risk factors from maternal demographic characteristics and medical history; in the presence of such factors, the patient is classified as high risk and in their absence as low risk. Although this approach is simple to perform, it has poor performance of the prediction of preeclampsia and does not provide patient-specific risks. This review describes a new approach that allows the estimation of patient-specific risks of delivery with preeclampsia before any specified gestational age by maternal demographic characteristics and medical history with biomarkers obtained either individually or in combination at any stage in pregnancy. In the competing risks approach, every woman has a personalized distribution of gestational age at delivery with preeclampsia; whether she experiences preeclampsia or not before a specified gestational age depends on competition between delivery before or after the development of preeclampsia. The personalized distribution comes from the application of Bayes theorem to combine a previous distribution, which is determined from maternal factors, with likelihoods from biomarkers. As new data become available, what were posterior probabilities take the role as the previous probability, and data collected at different stages are combined by repeating the application of Bayes theorem to form a new posterior at each stage, which allows for dynamic prediction of preeclampsia. The competing risk model can be used for precision medicine and risk stratification at different stages of pregnancy. In the first trimester, the model has been applied to identify a high-risk group that would benefit from preventative therapeutic interventions. In the second trimester, the model has been used to stratify the population into high-, intermediate-, and low-risk groups in need of different intensities of subsequent monitoring, thereby minimizing unexpected adverse perinatal events. The competing risks model can also be used in surveillance of women presenting to specialist clinics with signs or symptoms of hypertensive disorders; combination of maternal factors and biomarkers provide patient-specific risks for preeclampsia that lead to personalized stratification of the intensity of monitoring, with risks updated on each visit on the basis of biomarker measurements. How to calculate the risk of preeclampsia in women with a history of positive screeningAmerican Journal of Obstetrics & GynecologyVol. 223Issue 2PreviewWith the current demonstration of the benefits of aspirin initiated in early pregnancy to prevent the most severe and preterm forms of preeclampsia, there is a growing interest for the prediction of preterm preeclampsia in the first trimester of pregnancy.1 In the review by Wright et al,2 the authors reported that approximately 90% of women who will develop early preeclampsia could be identified using a competing risks approach in the first trimester of pregnancy, with a false-positive rate of 10%. Full-Text PDF" @default.
- W2986009663 created "2019-11-22" @default.
- W2986009663 creator A5004117088 @default.
- W2986009663 creator A5072511800 @default.
- W2986009663 creator A5080220991 @default.
- W2986009663 date "2020-07-01" @default.
- W2986009663 modified "2023-10-10" @default.
- W2986009663 title "The competing risk approach for prediction of preeclampsia" @default.
- W2986009663 cites W1154833837 @default.
- W2986009663 cites W1492212171 @default.
- W2986009663 cites W1540530901 @default.
- W2986009663 cites W1597497013 @default.
- W2986009663 cites W1910789778 @default.
- W2986009663 cites W1922557230 @default.
- W2986009663 cites W1972743675 @default.
- W2986009663 cites W1975775758 @default.
- W2986009663 cites W1983413616 @default.
- W2986009663 cites W1996307378 @default.
- W2986009663 cites W2006245385 @default.
- W2986009663 cites W2024837931 @default.
- W2986009663 cites W2033169404 @default.
- W2986009663 cites W2056250168 @default.
- W2986009663 cites W2065594976 @default.
- W2986009663 cites W2072253523 @default.
- W2986009663 cites W2074100793 @default.
- W2986009663 cites W2081876722 @default.
- W2986009663 cites W2094395765 @default.
- W2986009663 cites W2097871919 @default.
- W2986009663 cites W2130645342 @default.
- W2986009663 cites W2143180984 @default.
- W2986009663 cites W2144267311 @default.
- W2986009663 cites W2158619788 @default.
- W2986009663 cites W2161934818 @default.
- W2986009663 cites W2171322051 @default.
- W2986009663 cites W2176401980 @default.
- W2986009663 cites W2177734386 @default.
- W2986009663 cites W2178814194 @default.
- W2986009663 cites W2179705731 @default.
- W2986009663 cites W2179914493 @default.
- W2986009663 cites W2233974801 @default.
- W2986009663 cites W2320399814 @default.
- W2986009663 cites W2523964963 @default.
- W2986009663 cites W2524276500 @default.
- W2986009663 cites W2569868133 @default.
- W2986009663 cites W2597040732 @default.
- W2986009663 cites W2616583281 @default.
- W2986009663 cites W2730504020 @default.
- W2986009663 cites W2767859123 @default.
- W2986009663 cites W2790162931 @default.
- W2986009663 cites W2790948098 @default.
- W2986009663 cites W2808436993 @default.
- W2986009663 cites W2808569466 @default.
- W2986009663 cites W2811365965 @default.
- W2986009663 cites W2900398263 @default.
- W2986009663 cites W2900915766 @default.
- W2986009663 cites W2911558734 @default.
- W2986009663 cites W2923802759 @default.
- W2986009663 cites W3020830612 @default.
- W2986009663 cites W3022297674 @default.
- W2986009663 cites W4238988737 @default.
- W2986009663 cites W4241564905 @default.
- W2986009663 cites W4245514406 @default.
- W2986009663 cites W4251118184 @default.
- W2986009663 cites W4251335156 @default.
- W2986009663 doi "https://doi.org/10.1016/j.ajog.2019.11.1247" @default.
- W2986009663 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31733203" @default.
- W2986009663 hasPublicationYear "2020" @default.
- W2986009663 type Work @default.
- W2986009663 sameAs 2986009663 @default.
- W2986009663 citedByCount "117" @default.
- W2986009663 countsByYear W29860096632020 @default.
- W2986009663 countsByYear W29860096632021 @default.
- W2986009663 countsByYear W29860096632022 @default.
- W2986009663 countsByYear W29860096632023 @default.
- W2986009663 crossrefType "journal-article" @default.
- W2986009663 hasAuthorship W2986009663A5004117088 @default.
- W2986009663 hasAuthorship W2986009663A5072511800 @default.
- W2986009663 hasAuthorship W2986009663A5080220991 @default.
- W2986009663 hasConcept C105795698 @default.
- W2986009663 hasConcept C107673813 @default.
- W2986009663 hasConcept C12174686 @default.
- W2986009663 hasConcept C126322002 @default.
- W2986009663 hasConcept C131872663 @default.
- W2986009663 hasConcept C162324750 @default.
- W2986009663 hasConcept C187736073 @default.
- W2986009663 hasConcept C207201462 @default.
- W2986009663 hasConcept C2777218350 @default.
- W2986009663 hasConcept C2778376644 @default.
- W2986009663 hasConcept C2779234561 @default.
- W2986009663 hasConcept C3020404979 @default.
- W2986009663 hasConcept C33923547 @default.
- W2986009663 hasConcept C38652104 @default.
- W2986009663 hasConcept C41008148 @default.
- W2986009663 hasConcept C54355233 @default.
- W2986009663 hasConcept C57830394 @default.
- W2986009663 hasConcept C71924100 @default.
- W2986009663 hasConcept C86803240 @default.
- W2986009663 hasConcept C96250715 @default.